Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study

Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high grade adverse events. Anthropometrics and biomarkers of glucose metabolism were investigated in a observational study of 102 postmenopausal, HR + HER2- metastatic breast cancer patients treated with everolimu...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Sci Rep
Main Authors: Pizzuti, Laura, Marchetti, Paolo, Natoli, Clara, Gamucci, Teresa, Santini, Daniele, Scinto, Angelo Fedele, Iezzi, Laura, Mentuccia, Lucia, D’Onofrio, Loretta, Botticelli, Andrea, Moscetti, Luca, Sperati, Francesca, Botti, Claudio, Ferranti, Francesca, Buglioni, Simonetta, Sanguineti, Giuseppe, Di Filippo, Simona, di Lauro, Luigi, Sergi, Domenico, Catenaro, Teresa, Tomao, Silverio, Giordano, Antonio, Maugeri-Saccà, Marcello, Barba, Maddalena, Vici, Patrizia
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5587713/
https://ncbi.nlm.nih.gov/pubmed/28878375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-10061-2
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki